reports
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
SWK STANLEY BLACK & DECKER INC.
RGNX REGENXBIO INC.
RGP RESOURCES CONNECTION INC.
PLXS PLEXUS CORP.
PAYX PAYCHEX INC.
NVEE NV5 GLOBAL INC.
MMYT MAKEMYTRIP LTD.
MGRC MCGRATH RENTCORP
LNN LINDSAY CORPORATION
KRNT KORNIT DIGITAL LTD.
JRVR JAMES RIVER GROUP HOLDINGS LTD
HMN HORACE MANN EDUCATORS CORPORATION
BHLB BERKSHIRE HILLS BANCORP INC.
AOSL ALPHA & OMEGA SEMICONDUCTOR
ALB ALBEMARLE CORPORATION
BLUSD BELLUS HEALTH
EFR ENERGY FUELS
CLW CLEARWATER PAPER CORPORATION
SOM SOMNOMED
DLR DIGITAL REALTY TRUST INC.
LPLA LPL FINANCIAL HOLDINGS INC.
LPX LOUISIANA-PACIFIC CORPORATION
HRB H&R BLOCK INC.
WRB W. R. BERKLEY CORPORATION
BMTA BRITISH AMERICAN TOBACCO PLC ADS
SNDX SYNDAX PHARMACEUTICALS
RH RH
NTR NUTRIEN LTD.
ZS ZSCALER INC.
REPL REPLIMUNE GROUP
NTB BANK OF N.T. BUTTERFIELD & SON
DAVA ENDAVA PLC ADS
DDOG DATADOG INC CLASS A
DYN DYNE THERAPEUTICS
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
CNXC CONCENTRIX
ZWS ZURN WATER SOLUTIONS CORP
J JACOBS SOLUTIONS INC.
WOLF META WOLF AG
MED IGEAMED SPA
ADP A DONG PAINT JSC
- Dave Nicoski
- Ross LaDuke
PAG PENSKE AUTOMOTIVE GROUP INC
MNRO MONRO INC
GPC GENUINE PARTS COMPANY
GERN GERON CORP.
CRMT AMERICA'S CAR-MART INC.
AZO AUTOZONE INC.
AN AUTONATION INC.
ADMA ADMA BIOLOGICS INC
BLUSD BELLUS HEALTH
SAH SONIC AUTOMOTIVE INC. CLASS A
LKO LAKES OIL N.L.
ORLY O'REILLY AUTOMOTIVE INC.
SNDX SYNDAX PHARMACEUTICALS
SIGA SIGA TECHNOLOGIES INC.
TCDA TRICIDA
MIRM MIRUM PHARMACEUTICALS
RAPT RAPT THERAPEUTICS
CLDX CELLDEX THERAPEUTICS INC.
KDNY CHINOOK THERAPEUTICS INC
PRTS CARPARTS.COM INC
Bellus Health Inc: 1 director
A director at Bellus Health Inc sold 66,021 shares at 6.971USD and the significance rating of the trade was 84/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
BELLUS Health Announces Payment of $134,149 to Thallion CVR Holders
BELLUS Health Announces Payment of $134,149 to Thallion CVR Holders LAVAL, Quebec, Dec. 28, 2018 (GLOBE NEWSWIRE) -- BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical needs, today announced that it will pay an amount of $134,149 to the Contingent Value Rights (“CVR”) holders as provided in the agreements of the 2013 Thallion Pharmaceuticals Inc. (“Thallion”) acquisition by BELLUS Health. In accordance with the terms of the agreements of the 2013 Thallion acquisi...
BELLUS Health Closes $35M Financing to Support Development of its Lead...
BELLUS Health Closes $35M Financing to Support Development of its Lead Drug Candidate BLU-5937 for Chronic Cough Financing led by OrbiMed with Appointment of Mr. Chau Q. Khuong to BELLUS Board of Directors LAVAL, Quebec, Dec. 18, 2018 (GLOBE NEWSWIRE) -- BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has closed an equity offering, issuing a total of 36,842,105 common shares for gross proceeds of $35 million (the "Offering"). The Offering was led by OrbiMed and also included New Leaf Venture Partners, ...
BELLUS Health Announces Pricing of $35 Million Public Offering of Comm...
BELLUS Health Announces Pricing of $35 Million Public Offering of Common Shares NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES LAVAL, Quebec, Dec. 11, 2018 (GLOBE NEWSWIRE) -- BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced the pricing of its overnight marketed equity offering of $35 million of common shares at a price of $0.95 per share. The offering is being led by Bloom Burton Securities...
BELLUS Health Announces Overnight Marketed Equity Offering
BELLUS Health Announces Overnight Marketed Equity Offering Not for Distribution to United States Newswire Services or for Dissemination in the United States LAVAL, Quebec, Dec. 10, 2018 (GLOBE NEWSWIRE) -- BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced that it will undertake an overnight marketed offering of common shares. Bloom Burton Securities Inc. is acting as lead agent on behalf of a syndicate of agents that includes Mackie Researc...
BELLUS Health Announces Positive Top-Line Phase 1 Results for its Chro...
BELLUS Health Announces Positive Top-Line Phase 1 Results for its Chronic Cough Drug Candidate BLU-5937 - No Taste Loss at the Anticipated Therapeutic Doses - - BLU-5937 is Shown to be Safe and Well Tolerated - - Company Intends to Initiate a Clinical Phase 2 Study in Mid-2019; Top-line Results Expected in Mid-2020 - - BELLUS Health to Host Conference Call and Live Webcast Tomorrow at 8:00 AM Eastern Time - LAVAL, Quebec, Nov. 19, 2018 (GLOBE NEWSWIRE) -- BELLUS Health Inc. (TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therap...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Update: Moving closer to Kiacta Phase III data
Bellus’s lead candidate, Kiacta, continues to move forward in the pivotal Phase III trial for AA amyloidosis. Recruitment was completed in January 2015 with 261 patients and 80 of the required 120 events to complete study have already been triggered. Data is expected in 2016 and we estimate the probability of success at 60%, given positive efficacy trends in a previous Phase II/III study and design elements that could raise the likelihood of statistical separation vs placebo. The potential for...
Update: AA amyloidosis pivotal study fully enrolled
Bellus’s lead candidate, Kiacta, recently reached full recruitment for the pivotal Phase III trial for AA amyloidosis, with data expected in 2016. We estimate the probability of success at 60%, given positive efficacy trends in a previous Phase II/III study and design elements that could raise the likelihood of statistical separation vs placebo. Bellus’s partner, Auven Therapeutics, is funding a Phase II Kiacta study in sarcoidosis, to start in Q115. The potential for premium pricing and ext...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.